Trial record 1 of 1 for:
NCT01475266
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01475266 |
|
Recruitment Status :
Terminated
(Sponsor's decision)
First Posted : November 21, 2011
Last Update Posted : March 29, 2017
|
Sponsor:
Nippon Kayaku Co., Ltd.
Collaborator:
Handok Inc.
Information provided by (Responsible Party):
Nippon Kayaku Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety in patients with non-muscle invasive bladder cancer histologically diagnosed to be stage Ta and G1 or G2 and who were randomized into either an EO9 or placebo group after TURBT.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bladder Cancer | Drug: EO9 (Apaziquone) Drug: Placebo | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 51 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized, Placebo-controlled, Double-blinded Study of Single Immediate Instillation of EO9 After TURBT in Patients With NMIBC |
| Study Start Date : | November 2011 |
| Actual Primary Completion Date : | April 2013 |
| Actual Study Completion Date : | April 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Bladder cancer
MedlinePlus related topics:
Bladder Cancer
| Arm | Intervention/treatment |
|---|---|
| Experimental: EO9 (Apaziquone) |
Drug: EO9 (Apaziquone)
4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Other Name: Eoquin(R) |
| Placebo Comparator: Placebo |
Drug: Placebo
40 mL, Intravesical instillation, Single dose within 6 hours after TURBT |
Primary Outcome Measures :
- The recurrence rate at 2 years in patients with histologically diagnosed stage Ta, grade G1 or G2 bladder cancer [ Time Frame: 2 years ]
Secondary Outcome Measures :
- The recurrence-free interval in patients with histologically diagnosed stage Ta, grade G1 or G2 bladder cancer [ Time Frame: 2 years ]
- The progression rate [ Time Frame: 2 years ]
- The number of recurrences per patient [ Time Frame: 2 years ]
- The progression-free survival period [ Time Frame: 2 years ]
- The recurrence-free survival period [ Time Frame: 2 years ]
- The overall survival period [ Time Frame: 2 years ]
- The safety of EO9 [ Time Frame: 2 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients who have provided written informed consent
-
Patients who have urothelial cell carcinoma of the bladder with clinically apparent stage Ta, grade G1-G2 and satisfy both of the following criteria:
- The maximum number of tumors is 5.
- Each tumor diameter: ≤ 3.5 cm.
- Age: ≥20 years old at enrollment.
-
The functions of the major organs are adequate, and the following test value criteria are satisfied:
- Neutrophil count ≥1,500/μL
- Platelet count ≥10×10^4/μL
- Hemoglobin ≥10 g/dL
Exclusion Criteria:
- Patients with a single, primary bladder cancer of <0.5 cm.
- Patients with CIS lesions in the bladder or a history thereof.
- Patients with a history of other than stage Ta, histological grade G1 or G2 disease.
- Patients experiencing recurrence within 4 months following TURBT for prior NMIBC (duration between the last TURBT and cystoscopic confirmation of the present recurrence is within 4 months).
- Patients without at least a three-month cystoscopically confirmed recurrence-free interval between the last TURBT and the time of study screening
- Patients having a bladder tumor with a histological diagnosis other than urothelial carcinoma of the bladder or a history thereof.
- Patients who had been administered EO9 in the past.
- Patients who had been administered any other investigational drug within the past 30 days.
- Patients having a medical condition that would make it unsafe for them to undergo TURBT under general or spinal anesthesia.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01475266
Locations
Show 20 study locations
Sponsors and Collaborators
Nippon Kayaku Co., Ltd.
Handok Inc.
Investigators
| Study Director: | Yoshihiro Nambu, M.D., Ph.D. | Nippon Kayaku Co., Ltd. | |
| Study Director: | Woo Ick Jang, M.D., Ph.D. | Handok Inc. |
| Responsible Party: | Nippon Kayaku Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT01475266 |
| Other Study ID Numbers: |
A9EO9201 EO9_C301 |
| First Posted: | November 21, 2011 Key Record Dates |
| Last Update Posted: | March 29, 2017 |
| Last Verified: | April 2013 |
Keywords provided by Nippon Kayaku Co., Ltd.:
|
Bladder Cancer NMIBC TURBT |
Apaziquone EOquin Immediate instillation |
Additional relevant MeSH terms:
|
Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms |
Urinary Bladder Diseases Urologic Diseases Apaziquone Antineoplastic Agents |